Embark Welcomes New Scientific Advisory Board Ahead of Canine Health Summit 2022

Renowned scientific and medical experts selected to support and advise Embark in its quest to improve canine life and longevity

BOSTON, April 21, 2022 /PRNewswire/ — Embark Veterinary, Inc., the world leader in canine genetics, today announced its new Scientific Advisory Board ahead of its second annual Canine Health Summit. The new board members include some of the most distinguished members of the scientific community. They include three former biotech chiefs, two MacArthur Genius Prize winners and offer a variety of expertise in veterinary pathology, genomics, epigenetics and molecular diagnostic medicine.

The individuals who have chosen to join the board represent the scientific community’s keen interest in Embark’s work to add three years to the lifespan of dogs within the decade. It also demonstrates the confidence of human geneticists in the power of canine genetic health discoveries to potentially advance future human health discoveries.

“At Embark, we are proud to offer the most scientifically advanced canine DNA test available. That’s because we’re a company founded by two scientists, and also because we have access to the brightest and most innovative minds in human and canine genomics,” said Embark Chief Science Officer Adam Boyko. “Advice from experts who have made their own groundbreaking discoveries will inspire and guide our team as we seek to fulfill our mission of improving the life and longevity of all canines through science and technology.”

This new group of Scientific Advisory Board members Icontains:

  • David Botstein, PhD: Expert in the genetics of aging; Chief Science Officer at Calico Life Sciences
  • Carlo Bustamante, PhD: Population and Computational Genetics; Founder and CEO of Galatea Bio, Inc.
  • Jerry Lanchbury, PhD: human geneticist and specialist in molecular diagnostics; Chief Science Officer at Myriad Genetics
  • John Novembre, PhD: expert in population genomics; professor in University of Chicago Department of Human Genetics
  • Roberta Reford, DVM, MS, PhD, DACVIM, DACVP: Veterinarian with 30 years of experience in private practice, university teaching, research and commercial diagnostics; former Chief Medical Officer at IDEXX Laboratories
  • Jasper RinePhD: One of the founding scientists of the Dog Genome Project and Howard Hughes Medical Institute Professor and Distinguished Professor of Genetics, Genomics and Development at UC Berkeley

“Embark is doing some of the most exciting work in canine genetics today, and it’s clear what a significant impact it will have on veterinary medicine for years to come,” said Dr. Relford. “I am very pleased to offer my expertise in veterinary pathology and diagnostics to Embark’s leaders, scientists and engineers.”

Embark welcomes its new Scientific Advisory Board members as the second annual Canine Health Summit begins. Registered for 27-28 April, panels will be devoted to a variety of topics, including canine cancer, breeding practices, problem behaviors, disc extrusion, and even human-canine bonding. The event will be virtual and free, and open to anyone interested in learning more about the future of pet ownership.

“The Canine Health Summit is one of the few opportunities for veterinarians, breeders, researchers, scientists and dog owners to come together and learn from each other how to extend and improve the lives of all dogs,” said Dr. Jacquelyn Evansassistant professor at Cornell’s Keynote presenter for the Baker Institute for Animal Health and the Canine Health Summit. “Together we have the strength to overcome challenges as difficult as canine cancer, which affects nearly half of dogs over the age of 10.”

Veterinarians, breeders, dog owners, scientists and others interested in learning more about canine health can view the 2022 Canine Health Summit agenda and register at Labroots.

About Embarkation
Embark Veterinary, Inc. was founded in 2015 by two brothers, Adam and Ryan Boykowho have a passion for scientific research and a lifelong love of dogs. Powered by its world-class canine DNA test, Embark is building a powerful platform for scientific discovery that will accelerate advances in personalized canine care. Embark offers the most scientifically advanced, trusted, and top-rated canine DNA tests on the market, helping dog owners, breeders, and veterinarians learn more about their dog’s breed, health, and lineage. Customers receive hundreds of actionable insights that help provide more proactive care, and each test fuels new research to help all dogs live longer, healthier lives. Embark is an official research partner of Cornell University College of Veterinary Medicine, has been included and included in the Inc. 5000 list for the past two years forbes‘ List of Next Billion Dollar Startups.

For more information, visit Embark’s website at EmbarkVet.comand follow Embark on Facebook, Twitterand Instagram.

SOURCE Embark Veterinary, Inc.

About Clayton Arredondo

Check Also

Family staggers after dog bite, killing healthy Northern Ontario man

Sylvain Boissonneault died June 8 in Health Sciences North, days after being bitten by his …